Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
RESEARCH TOOLSreports
Enliven Therapeutics (ELVN) Stock Price & Analysis
264 Followers
ELVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.80 - $26.00
Previous Close$17.18
Volume792.79K
Average Volume (3M)262.87K
Market Cap
$804.12M
Enterprise Value$540.64M
Total Cash (Recent Filing)$263.48M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-7.9
Beta0.92
Next Earnings
May 09, 2024EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding41,347,632
10 Day Avg. Volume321,526
30 Day Avg. Volume262,867
Standard Deviation0.30
R-Squared0.03
Alpha-0.00773
Financial Highlights & Ratios
Price to Book (P/B)2.71
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-14.14
Forecast
1Y Price Target
$35.50Price Target Upside104.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Enliven Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyELVN-001 shows promise in patients previously resistant to multiple lines of therapy, potentially representing a significant advancement in treatment options.
Leadership ConfidenceThe transition of Dr. Lori Kunkel to the Board of Directors from a scientific advisor role signifies strong internal confidence in ELVN's direction and pipeline.
Market PotentialAnalysts suggest that recent positive data on ELVN-001 is not yet reflected in the stock price, presenting an opportunity for value discovery.
Bears Say
Analyst IntegrityMizuho Securities may have a conflict of interest that could affect the objectivity of this report.
Financial PerformanceELVN reported a net loss, which could signal financial instability and affect investors' confidence.
Market SentimentShort Interest (% Float) is high at 20.5%, indicating that a significant portion of the company's tradable shares are being shorted.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $9.80 and its highest was $26.00 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Currently, no data Available
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 8 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Mar 14, 2024. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.537 by $0.067.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -$0.54.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 46,805,378 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.537. Following the earnings report the stock price went up 3.726%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Among the largest hedge funds holding Enliven Therapeutics’s share is Fairmount Funds Management Llc. It holds Enliven Therapeutics’s shares valued at 29M.
---
Enliven Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.50 (104.14% Upside)
$35.50 (104.14% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $19.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.56%
12-Months-Change
Fundamentals
Return on Equity
-42.60%
Trailing 12-Months
Asset Growth
195.64%
Trailing 12-Months
Company Description
Enliven Therapeutics
Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin.
---
ELVN Stock 12 Months Forecast
Average Price Target
$35.50
▲(104.14% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Curis
―
Vertex Pharmaceuticals
―
Best Analysts Covering ELVN
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+18.49%
reiterated a buy rating 21 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +18.49% per trade.
---